Otsuka (OTCMKTS:OTSKY) Downgraded by Zacks Research to “Hold”

Otsuka (OTCMKTS:OTSKY – Get Free Report) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks reports.

Otsuka Stock Down 1.0%

OTCMKTS:OTSKY opened at $37.68 on Monday. The firm’s 50-day moving average price is $37.29 and its 200-day moving average price is $35.15. The company has a market capitalization of $40.48 billion, a PE ratio of 16.17, a P/E/G ratio of 2.75 and a beta of 0.08. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.21 and a quick ratio of 1.65. Otsuka has a 1-year low of $26.11 and a 1-year high of $40.92.

Otsuka (OTCMKTS:OTSKY – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. The company had revenue of $4.51 billion during the quarter, compared to analysts’ expectations of $4.42 billion. Otsuka had a net margin of 14.36% and a return on equity of 11.90%. On average, equities analysts predict that Otsuka will post 2.21 EPS for the current fiscal year.

About Otsuka

(Get Free Report)

Otsuka Holdings Co., Ltd. is a Japan-based holding company whose businesses focus primarily on pharmaceuticals and nutraceuticals. Its group companies research, develop, manufacture, and market prescription medicines, consumer health products, and medical devices. Otsuka’s pharmaceutical portfolio includes treatments across areas such as mental health, kidney disease, and oncology. Its nutraceutical business offers products including Pocari Sweat and CalorieMate, alongside other nutrition and wellness products.

See Also

Receive News & Ratings for Otsuka Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otsuka and related companies with MarketBeat.com's FREE daily email newsletter.